J Cancer Ther：Lunasin可以降低94%的转移性肿瘤！降低肝脏中的转移性肿瘤6倍！

查看全部

马上注册，结交更多好友，享用更多功能，让你轻松玩转社区。

您需要登录才可以下载或查看，没有账号？立即注册

x

2013年7月10日讯--近日，来自伊利诺伊大学的研究者通过对小鼠研究揭示，摄入大豆肽lunasin可以明显降低其结肠癌的转移，研究者希望深入研究来揭示lunasin是通过什么机制来影响癌症的转移的，相关研究成果刊登于国际杂志Journal of Cancer Therapy上。

研究者Elvira de Mejia表示，这项研究中我们发现，给小鼠口服20mg的大豆肽lunasin可以降低94%的转移性肿瘤；摄入unasin可以同化疗药物奥沙利铂一起联合使用来产生更为明显的结果，可以使得肝脏中的转移性肿瘤降低6倍。

研究者发现，lunasin可以渗入到癌细胞中引发其死亡，而且可以和至少一种转移性癌细胞上的受体进行结合。研究者表示，毕竟大豆是一种食物，我们想让动物以食物的方式消耗它，由于lunasin可以被消化，因此我们需要计算出具体的服用量来达到期望的血液浓度，以发挥最佳的效果。

当给实验动物按照8mg/kg服用lunasin时，可以降低肿瘤数量达到55%，研究者通过不断增加剂量来进行测试，最终发现，当lunasin剂量为20mg/kg时，其降低肿瘤的数量就可以达到94%。最后研究者检测发现20mg/kg和30mg/kg的lunasin的作用是相当的，其或许就可以作为日常的建议服用量，研究者表示，当然一些食品公司也会提供富含lunasin的豆奶或者酸乳给消费者。

Lunasin在机体组织尤其是肝脏中可以大量积累，日常饮食中消耗这种蛋白不仅是很有营养的，而且也可以预防癌症的发生。研究者目前计划开展一项长达一年的研究来通过在转基因结肠癌小鼠中模拟lunasin的积累影响作用，从而来更深入研究其对机体抗癌的作用机制；当然这项研究需要进行大量临床前试验来确定。
Potential of Lunasin Orally-Administered in Comparison to Intraperitoneal Injection to Inhibit Colon Cancer Metastasis in Vivo

Vermont P. Dia, Elvira Gonzalez de Mejia

Lunasin is a bioactive peptide originally isolated from soybean and has demonstrated chemopreventive and anti-cancer properties against skin, colon and breast cancers. The objective of the study was to evaluate the capability of intraperitoneally and orally-administered soybean-derived peptide lunasin to inhibit KM12L4 human colon cancer cell metastasis in a mouse model. Intraperitoneal (i.p.) injection of lunasin (4 mg/kg bw/day) reduced the number of liver metastasis by 50% (P = 0.047) and the liver weight/body weight ratio by 23% (P = 0.039). Oral administration of lunasin reduced the number of liver metastasis by 56% (8 mg/kg bw/day, P = 0.293) and 94% (20 mg/kg bw/day, P = 0.247). Immunohistochemical staining of the liver-tissue section showed that lunasin at 20 mg/kg bw dose did not significantly reduce the expression of proliferating cell nuclear antigen, increased the expression of proapoptotic Bax by 2.7-fold but also increased the expression of the antiapoptotic Bcl-2 by 3.8-fold. Regarding epigenetic markers, H3K18 was not significantly affected by either oral dose while H4K8 was dose dependently increased by 2.3-fold (P = 0.001, 8 mg/kg bw) and 2.7-fold (P < 0.001, 20 mg/kg bw). On the other hand, i.p. injection of lunasin reduced both histone acetylation markers significantly. The difference on the effects can be attributed to the different routes of administration used leading to digestion of lunasin when given by oral gavage. In conclusion, lunasin reduced colon cancer metastasis in vivo; however, more studies are needed to determine the oral dose of lunasin and prevent colon cancer metastasis.